X4 Pharmaceuticals (XFOR) Current Deferred Revenue (2018 - 2025)

X4 Pharmaceuticals (XFOR) posted Current Deferred Revenue of $464000.0 for Q4 2025, down 21.62% on a QoQ basis from $592000.0 in Q3 2025.

X4 Pharmaceuticals (XFOR) Current Deferred Revenue (2018 - 2025) Analysis & Trends

X4 Pharmaceuticals' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $464000.0 for Q4 2025.

Quarterly Current Deferred Revenue changed N/A year-over-year to $464000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $464000.0 (changed N/A YoY) and the FY2025 annual result came in at $464000.0, changed N/A from the prior year.
Current Deferred Revenue was $464000.0 for Q4 2025 at X4 Pharmaceuticals, down from $592000.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $855000.0 in Q1 2025 and bottomed at $464000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	X4 Pharmaceuticals	167.90 Mn	-49.15 Mn	2.20 Mn

Download Data